Beranda › Leukemia Mieloid Akut › Kansas › Overland Park
Uji klinis Leukemia Mieloid Akut di Overland Park, KS
11 studi untuk Leukemia Mieloid Akut mencari peserta di lokasi sekitar Overland Park (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Menerima pesertaFase 2
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Menerima pesertaFase 3
- US-Kansas City KS-KUMC, Fairway · 3 mi jauhnya
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Menerima pesertaFase 1
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- University of Kansas Clinical Research Center, Fairway · 3 mi jauhnya
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Menerima pesertaFase 1
- The University of Kansas Medical Center Research Institute, Fairway · 3 mi jauhnya
APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML
Menerima pesertaFase 1
- University of Kansas, Fairway · 3 mi jauhnya
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
Menerima pesertaFase 2
- University of Kansas Cancer Center, Fairway · 3 mi jauhnya
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Menerima pesertaFase 1
- University of Kansas Cancer Center, Fairway · 3 mi jauhnya
Uji klinis Leukemia Mieloid Akut di kota lain
- Houston, TX85 studi
- New York City, NY51 studi
- Boston, MA44 studi
- Seattle, WA41 studi
- Baldwin Park, CA40 studi
- Columbus, OH35 studi
- Philadelphia, PA34 studi
- Durham, NC33 studi
- Atlanta, GA31 studi
- Tampa, FL29 studi
- Chicago, IL26 studi
- Portland, OR25 studi
Studi lain di Overland Park
- Kanker Paru Non-Sel Kecil16 studi
- Kanker Paru11 studi
- Kanker Payudara10 studi
- Fibrilasi Atrium8 studi
- Kanker Kolorektal8 studi
- Obesitas7 studi
- Kanker Pankreas7 studi
- Kanker Prostat7 studi
- Melanoma6 studi
- Kelebihan Berat Badan6 studi
- Kanker Ovarium6 studi
- Kanker (semua jenis)5 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.